### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	J ,	

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average k	ourdon							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

#### Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

37 hours per response: 0.5

1. Name and Address of Reporting Person*  Gibbs Michael Terrence					2. Issuer Name <b>and</b> Ticker or Trading Symbol T2 Biosystems, Inc. [ TTOO ]									neck all app Direc	licable) tor	ng Per	rson(s) to Iss	wner	
(Last)	(FI	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/09/2020								Officer (give title below) below  General Counsel			specify		
(Street) LEXINC			02421 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Lir	e) X Form Form	or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson					
		Tab	le I - Nor	n-Deriv	ative	Sec	curitie	s Ac	quired,	Dis	posed (	of, o	r Ben	eficia	lly Owne	d			
			2. Transaction Date (Month/Day/Year)		r) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction   Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				Benefi	ties cially Following	Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount		(A) or (D)	Price	Transa	ction(s) 3 and 4)			(111501.4)
Common	Stock			02/09	/2020				М		5,833	3	A	(1)	5	9,787		D	
Common	Stock			02/11	/2020				<b>S</b> <sup>(2)</sup>		3,200	0	D	\$0.77	<sup>7(3)</sup> 5	6,587	D		
		Т	able II -	Deriva (e.g., p	tive S uts, c	ecu calls	rities , warr	Acqu ants	uired, E , optior	Dispo	osed of onverti	, or ble	Bene secur	ficially ities)	/ Owned				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C					ransaction of ode (Instr. Derivative		tive ties red sed	6. Date Exercisable and Expiration Date (Month/Day/Year)						8. Price of Derivative Security (Instr. 5)		ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisab		expiration Pate	Title		or Number of Shares					
Restricted Stock	(1)	02/09/2020		T	м		5 833		(4)		(4)	Con	nmon	5.833	\$0.00			D	

## **Explanation of Responses:**

- 1. Each restricted stock units ("RSU's") represents a contingent right to receive one share of the Issuer's common stock.
- 2. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2018.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from \$0.77 to \$0.78. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. On February 9, 2017 the reporting person was granted 17,500 RSU's that vested in three equal annual installments beginning on February 9, 2018.

# Remarks:

Units

/s/ John Sprague, Attorney-infact

02/12/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.